Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Spark Therapeutics (NASDAQ:ONCE) and Xoma Corp (NASDAQ:XOMA).
Spark Therapeutics (ONCE)
William Blair analyst Raju Prasad maintained a Buy rating on Spark Therapeutics today. The company’s shares opened today at $57.86.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 12.5% and a 51.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Audentes Therapeutics.
Currently, the analyst consensus on Spark Therapeutics is a Moderate Buy with an average price target of $71.50, representing a 23.6% upside. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $103 price target.
.
See today’s analyst top recommended stocks >>
Xoma Corp (XOMA)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Xoma Corp. The company’s shares opened today at $16.35, close to its 52-week low of $15.35.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.7% and a 57.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.
Xoma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $49.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.